Immunosuppressives can, for convenience, be divided into two broad classes, the antiproliferative agents and the 'others'. The antiproliferatives are those in which the immunosuppression seems, on good evidence, to be due to interference with cell reproduction. The 'others' are agents for which such evidence is scanty or non-existent or for which there is evidence of quite other modes of action (Table 1) .
The antiproliferative agents appear to act primarily by impairing cell reproductive integrity. This means that the affected cells may remain alive and may continue to carry out many of their functions, but are unable to reproduce successfully. Synthesis of DNA, RNA and other cell constituents may continue at the normal rate (Levis et al. 1965 , Rosenberg & Gregg 1969 , but the cell either fails to divide, forming a giant cell, or it commences a division that it cannot complete, or it divides unsuccessfully, with chromosomes unequally shared between the daughter cells or damaged in some way (Nasjletti & Spencer 1966 , Court-Brown et al. 1967 ). These lesions may eventually lead to cell death but, even when they do not, the affected cells are 'dead' so far as their reproductive abilities are concerned.
This type of damage, which has been observed after administration of nearly all the antiproliferative agents listed in Table 1 , is to be sharply distinguished from the rapid destruction of small lymphocytes seen after administration of some agents, particularly X-radiation, corticosteroids, nitrogen mustards and actinomycin. While it might seem only reasonable to attribute immuno-suppression in such cases to widespread lymphocyte destruction, it must be pointed out that there are many powerful immunosuppressives, particularly the antimetabolites, that do not have this effect and some rather ineffective ones, e.g. colchicine, that do.
The reasons for believing that impairment of cell reproductive integrity is the basic mode of action of the antiproliferative agents are considered in detail elsewhere (Berenbaum 1969a (Berenbaum , 1970 . Briefly, they are as follows.
Correlation of immunosuppressive and antitumour activity: Almost all effective antitumour agents are immunosuppressive. Not only this; where one and the same agent is used clinically or experimentally either to treat neoplasms or as an immunosuppressive (e.g. azathioprine, cyclophosphamide), the dosage that has been found to be the most useful is virtually the same for either purpose (Rundles et al. 1961 , Starzl 1964 Holcomb 1967 , White et al. 1966 ). These striking correlations, which hold for a variety of agents in different species (Berenbaum 1970) , suggest that the mode of action of these agents on immunocytes is likely to be the same as their mode of action on tumour cells.
A good deal of light has been thrown on the latter by the work of Skipper and his colleagues (reviewed by Skipper 1968) . By cell-transfer experiments these workers have shown that the reason why tumours slow down in growth or regress after treatment with an antitumour drug is not that the whole tumour cell population has been slowed in growth, nor that treatment has selectively preserved the slower growing cells, nor that there is a temporary halt to growth, but that part of the population has in effect disappeared as a reproducing entity, the remaining cells carrying on growing very much as before. There is good evidence that the cells that have 'disappeared' are not dead; they have simply been sterilized (Hofer etal. 1969 ).
Time-dependent effects of immunosuppressive agents: Most agents that impair cell reproductive integrity do so most effectively if the cells concerned are multiplying rapidly at the time they are exposed to the agent. This applies to such agents as methotrexate, 6-mercaptopurine, 5-fluorouracil, vincaleukoblastine and actinomycin (Bruce et al. 1966 , Schabel et al. 1965 . Timing experiments have clearly shown that agents of this sort interfere maximally with immune responses if they are given during the few days following administration of antigen, when the cells concerned are proliferating most rapidly. Administration before the antigen, when immunocytes are not rapidly multiplying, is ineffective (Berenbaum 1962 , Brown 1964 , Uyeki 1967 , Gisler & Bell 1969 .
Radiation, on the other hand, is able to impair cell reproductive integrity whether the cells are multiplying or not. If they are not proliferating at the time of irradiation, the damage is stored, sometimes for months or years, until proliferation is induced. If the immunosuppressive effects of radiation are due to impairment of cell reproductive integrity, we would expect radiation to be effective if given before the antigen and its effects to be long-lasting. Both these expectations are borne out in practice (Gengozian & Makinodan 1958 , Taliaferro & Taliaferro 1964 .
The conclusion is inescapable that the main mode of action of immunosuppressive agents of the antiproliferative class is impairment of the reproductive integrity of cells that mediate the immune response.
Interference with cell reproductive integrity is, of course, not the whole story, even for the known Broken lines indicate steps, the occurrence or role of which is uncertain. TP, thymus-processed lymphocytes.
NTP, non-thymus-processed lymphocytes antiproliferative agents. X-rays, for example, probably impair macrophage function (Gallily & Feldman 1967 , Pribnow & Silverman 1969 . The corticosteroids, which inhibit proliferation of lymphoid cells, also interfere with macrophage function and, in cell-mediated immunity, protect target cells from damage by activated lymphocytes. Whether antilymphoid sera impair lymphocyte reproductive integrity is unknown, although there is evidence that they have this effect on bone marrow cells (Seller & Polani 1969 , De Meester et al. 1968 , Harris et al. 1969 . The main effect of such sera appears to be on circulating thymusprocessed lymphocytes which are believed to be damaged and rendered susceptible to phagocytosis (Martin & Miller 1967) .
Some of the known sites of action of various immunosuppressive agents are shown in Fig 1. Mechanisms ofImpairment of Cell Reproductive Integrity There are two principal known ways by which antiproliferative agents affect the ability of cells to reproduce: (a) by inhibiting the enzymes mediating the syntheses essential for cell reproduction, and (b) by interfering with the templates used by some of these enzymes for the assembly of complex macromolecules.
Enzyme inhibition is a principal feature of antimetabolite action. It may be brought about either by competition between substrate and antimetabolite for the same binding site on the enzyme molecule, or by the antimetabolite mimicking normal product-inhibition.
The product of an enzyme-mediated reaction is often able to combine with an enzyme molecule, at a site other than the substrate binding site, in such a way as to distort the molecule and prevent Section ofPathology somes and cause a 'misreading' of the information in attached messenger RNA. it from binding its substrate. Generally, the enzyme affected is one mediating the first of a chain of reactions and the normal inhibitor is the final product of the chain. The virtue of this mechanism is that it controls the amount of the final product by switching off the chain of reactions at its inception. Some immunosuppressives, for instance 6-mercaptopurine, may be metabolized in the same way as normal substrates and the products of such metabolic reactions can inhibit various enzymes just as normal products can (Bennett et al. 1963 ).
The templates concerned in cell reproduction are the DNA and messenger RNA molecules. Associated with these are the transfer RNA molecules and ribosomes that enable messenger RNA templates to act in protein synthesis. There are many ways in which immunosuppressives can interfere with the functioning of this complex system. Some of these are illustrated in Fig 2. The DNA chain may be split by X-rays or mitomycin. The complementary strands of the DNA helix may be chemically cross-linked by alkylating agents or mitomycin. The information encoded in the sequences of nucleic acid bases may be altered by substitution of abnormal purine or pyrimidine bases, such as 6-thioguanine or 5fluorouracil, for normal ones. The ability of DNA to act as a template for RNA synthesis may be reduced by agents such as the actinomycins, which bind tightly to the minor groove on the DNA double helix and so prevent access of RNA polymerase. The attachment of messenger RNA to the ribosomes may be prevented by chloramphenicol. The aminonucleoside antibiotics (streptomycin, neomycin) also attach to ribo-
The Problem ofToxicity
The difficulties in using antiproliferative agents stem largely from the fact that they impair the reproductive integrity not only of lymphoid cells but of any proliferating cells, including those of bone marrow, intestinal epithelium and skin. With these agents there is always likely to be a problem in steering between therapeutic effect and intolerable toxicity. Fortunately, this is not insoluble. Agents of other groups may not pose this particular problem, but they do pose others (Doak et al. 1969 ).
The Searchfor New Drugs It is obvious that various agents differ very much in the ratio between therapeutically effective and toxic doses. With drugs like azathioprine and cyclophosphamide this ratio is high and it is often possible to obtain highly satisfactory effects with negligible or only moderate toxicity. It would be difficult to do this with, say, nitrogen mustard or actinomycin D, and practically impossible with whole-body irradiation. These differences in therapeutic ratio are due to the differences between various cell types in the factors that affect their sensitivity to drugs, such as (a) rate of uptake of the drug, rate of metabolism of the drug to an active or inactive form, dependence on particular metabolic paths blocked by the drug, ability to repair the damage it causes, and so on, and (b) the differences between various drugs in factors that affect their ability to enter and damage cellslipid solubility, molecular size, rate of hydrolysis, ability to undergo various types of molecular bonding to cell constituents, &c.
It is exceedingly unlikely that the agents we find most useful now happen to have the optimum combination of all these factors. Undoubtedly, therefore, the search for better agents is bound to succeed. Such a search can be carried on by the more or less blind technique of screening, but it would be more economical in the long run, and more interesting, to study in detail the factors that determine selectivity of action of drugs and to use this information to design new drug molecules on a rational basis.
Combined Therapy While we can use synergistic combinations of drugs, this would be of little use if a synergistic effect in immunosuppression were accompanied by an equal or greater synergy with regard to bone marrow toxicity. The type of synergy we are looking for is synergy with regard to therapeutic ratio, and therapeutic effect and toxicity cannot be considered apart here. A good example of such synergy is provided by the use of agents which are not in themselves immunosuppressive but are able to protect non-lymphoid tissues from the toxic effects of immunosuppressive agents. Folinic acid, for instance, does not alter the immunosuppressive effect of methotrexate in the guinea-pig, but it greatly reduces its toxic effects, so that a considerable increase in therapeutic ratio results from administering both agents (Berenbaum 1964) .
Design ofSelective Dose Regimens Another way of tackling the problem of toxicity is to adapt the therapeutic schedule, i.e. dose size and frequency, so as to exploit differences in drug sensitivity and proliferative or recuperative rate between various cell populations. Let us artificially simplify this problem to the point where we are considering only two cell populations, one of immunocytes which we wish to damage as much as possible, and the other of a vital and vulnerable cell population, such as bone marrow, which we wish to conserve as much as possible. Both these cell populations exist in the same individual, so that we cannot produce the widely divergent effects we are aiming at by using two different dose regimens; the one regimen has to achieve both purposes.
Relative to each other, the two cell populations may be either sensitive or insensitive to the drug, i.e. a given dose will produce either a larger or smaller depletion. Further, the recovery from depletion of each population will be relatively either fast or slow. Now it is evident that sensitive cells will be damaged by only small doses of drug and insensitive cells will require large doses. Similarly, a cell population that recovers rapidly from depletion will require frequent doses of drug to keep it depleted whereas a population that recovers slowly would require only infrequent doses. While this may appear to be stating the obvious, an interesting conclusion follows when the various possible combinations of these characteristics are considered, as in Table 2. There is no problem about the sensitive, slowly recovering population or the insensitive, rapidly recovering population. The one will be more damaged and the other less damaged than any other type of population by any dose regimen. But suppose one of the cell populations we are con- sidering is sensitive and rapidly growing and the other is insensitive and slowly growing. The optimum regimen for eliminating the former while conserving the latter will be one of small frequent doses, while the reverse effect will follow from a regimen of massive, infrequent doses. If we knew what categories our immunocyte and bone marrow populations belonged to, we could choose the type of regimen that would achieve the desired result. I have dealt with this problem only in general terms here. A fuller treatment, and its mathematical basis, is given elsewhere (Berenbaum 1969b) . This would seem to be a promising field for clinical research. We already know that, in the chemotherapy of leukimia, the effectiveness of a drug may depend to a considerable degree on the relation between dose size and frequency. The difficulty in applying these considerations to clinical immunosuppression is that we know very little as yet of the sensitivity of human lymphoid cells to drugs, and of their rates of recovery after drug-induced depletion.
